Anebulo Pharmaceuticals ANEB 深 沪
已收盘 08-01 16:00:00 美东时间
2.85
+0.180
+6.74%
华盛通- 最 高2.92
- 今 开2.70
- 成交量 14.28万股
- 最 低 2.67
- 昨 收 2.67
- 总市值 1.17亿
- 52周最高 3.42
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.8001
- 委 比 -95.01%
- 总股本 4108.47万
- 历史最高 9.33
- 量 比 0.50
- 振 幅 9.36%
- 历史最低 0.8001
- 每 手 1
- 风险率 0.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | 肠炎新药临床试验进展积极，ABVX飙涨超580%！ANEB大涨超80%
肠炎新药临床试验进展积极，ABVX飙涨超580%！公司宣布高溢价私有化计划，ANEB大涨超80%>>
07-24 19:53
Maxim Group Downgrades Anebulo Pharmaceuticals to Hold
Maxim Group analyst Michael Okunewitch downgrades Anebulo Pharmaceuticals (NASDAQ:ANEB) from Buy to Hold.
07-24 05:41
Anebulo approves reverse stock split ahead of going-private transaction
Anebulo Pharmaceuticals (NASDAQ:ANEB) added ~75% on Wednesday after a special panel of its independent directors approved a reverse stock split as part of the company’s plans to go private and end its...
07-24 02:58
Anebulo Pharmaceuticals Announces Plan to Go Private
Anebulo Pharmaceuticals ( ($ANEB) ) has issued an announcement. On July 23, 202...
07-23 20:48
Anebulo Pharmaceuticals Approves Plan For Reverse Stock Spilt Of Not Less Than 1-For-2500 And Not More Than 1-For-7500. As Proposed Stockholders Will Receive $3.50 Per Pre Spilt Share
Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced
07-23 20:13
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
Anebulo Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 EPS results.
Anebulo Pharmaceuticals shares are trading higher after the company reported be...
05-14 23:06
Anebulo Pharmaceuticals Q3 EPS $(0.04) Beats $(0.05) Estimate
Anebulo Pharmaceuticals (NASDAQ:ANEB) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 33.33 percent increase over losses of $(0.06) per share
05-14 06:26
Anebulo Pharmaceuticals Reports Fiscal Q2 2025 Results
Anebulo Pharmaceuticals, Inc. ( ($ANEB) ) has released its Q2 earnings. Here is...
02-19 11:54
